Investor Presentation
17
Investor presentation
First six months of 2022
Financial outlook for 2022
Sales growth - at CER
Expectations
3 August 2022
12% to 16%
Expectations
29 April 2022
10% to 14%
Sales growth - reported
Operating profit growth - at CER
Operating profit growth - reported
Around 9 percentage points higher
11% to 15%
Around 14 percentage points higher
Around 7 percentage points higher
9% to 13%
Around 11 percentage points higher
Financial items (net)
Effective tax rate
Free cash flow
Loss of around DKK 5.5 billion
20% to 22%
DKK 57 to 62 billion
Loss of around DKK 4.1 billion
Note: Changes since last highlighted in bold
The financial outlook is based on an assumption of a continuation of the current business environment and given the current scope of business activities and has been prepared assuming that currency
exchange rates remain at the level as of 1 August 2022
20% to 22%
DKK 55 to 60 billion
Novo NordiskⓇView entire presentation